|
Lung Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses.
|
23548910 |
2013 |
|
Lung Neoplasms
|
0.370 |
AlteredExpression
|
group |
LHGDN |
Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer.
|
15375490 |
2004 |
|
Lung Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
Here we focus on MMP-1, showing that in lung tumors, MMP-1's cognate mRNA is strongly expressed in stromal fibroblasts adjacent to EMMPRIN-expressing tumor cells.
|
9877171 |
1998 |
|
Lung Neoplasms
|
0.370 |
Biomarker
|
group |
LHGDN |
[Association of MMP1 -1607(1G>2G)single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality].
|
16767672 |
2006 |
|
Lung Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
Targeting of xenograft and orthotopic lung tumors was demonstrated with fluorescent (DiR) CLG carriers in mice.
|
24727000 |
2014 |
|
Lung Neoplasms
|
0.370 |
Biomarker
|
group |
LHGDN |
Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer.
|
18483334 |
2008 |
|
Lung Neoplasms
|
0.370 |
GeneticVariation
|
group |
LHGDN |
Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer.
|
16311244 |
2006 |
|
Nephrotic Syndrome
|
0.200 |
Biomarker
|
group |
CTD_mouse |
Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats.
|
1281619 |
1992 |
|
Cardiomyopathy, Dilated
|
0.120 |
GeneticVariation
|
group |
LHGDN |
Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population.
|
18028894 |
2007 |
|
Cardiomyopathy, Dilated
|
0.120 |
AlteredExpression
|
group |
BEFREE |
Collagen I and III, MMP-1 and TIMP-1 immunoexpression in dilated cardiomyopathy.
|
29250654 |
2017 |
|
Cardiomyopathy, Dilated
|
0.120 |
Biomarker
|
group |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, high-throughput analysis of Cancer Genome Atlas data identified distinct targets, including Fatty acid synthase FASN and Matrix Metallopeptidase 1 MMP1 as novel, promising combination therapy partners.
|
30283446 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whole proteome mass spectrometry analysis showed an enrichment of cell adhesion and cell to matrix interaction proteins, notably, matrix metalloproteinase-1 (MMP1) and beta-catenin (CTNNB1), which are known to play critical roles in cancer metastasis. shYB-1 cells exhibited substantial downregulation of MMP1 and CTNNB1 mRNA and protein expression, with reduced MMP1 enzyme activity.
|
30905819 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Resistant cells expressed higher levels of genes coding for cancer stem cell markers (JARID1B, CD271 and Fibronectin) as well as genes involved in drug resistance (ABCG2), cell invasion and promotion of metastasis (MMP-1 and MMP-2).
|
25725450 |
2015 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Rapid genotype analysis of the matrix metalloproteinase-1 gene 1G/2G polymorphism that is associated with risk of cancer.
|
10842101 |
2000 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The authors hypothesized that this MMP-1 polymorphism may affect susceptibility to the development and progression of cancer.
|
21523769 |
2011 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A subgroup analysis of the clinicopathologic parameters in cancer group also showed no significant difference suggesting the lack of an association between SNP of the MMP-1 promoter -1607 bp region and cervical cancer invasiveness.
|
15617836 |
2005 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The distribution of 2G/2G, 1G/2G and 1G/1G for MMP1 promoter 1607 genotype was 36.8%, 40.2% and 23.0% in the oral cancer group and 34.3%, 44.9% and 20.8% in the non-cancer control group, respectively (p for trend=0.1454).
|
27381606 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our recent work demonstrates that DR5 suppression promotes cancer cell invasion and metastasis through caspase-8/TRAF2-mediated activation of ERK and JNK signaling and MMP1 elevation.
|
28482915 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DAVID annotation indicated that COL1A1 and MMP1 could be potent biomarkers for EAC and BE, respectively, since they participate in the majority of the enriched KEGG and GO terms that are important for inflammation and cancer.
|
30670912 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer.
|
15475433 |
2004 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
At noncytotoxic concentrations, i.e., concentrations lower than those normally used in cancer chemotherapy, the anthracycline doxorubicin specifically inhibited collagenase 1 (MMP-1) gene expression in the highly invasive and metastatic human melanoma cell line A2058.
|
9918220 |
1999 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We tested the possible association of MMP1 and MMP8 gene variation with these two types of cancer.
|
21642878 |
2011 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A single nucleotide polymorphism in the promoter region of -1607 bp of the human matrix metalloproteinase-1 (MMP-1) gene has been found to be associated with an increased risk of various inflammatory diseases and cancer metastasis.
|
16302919 |
2005 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A single nucleotide polymorphism was described in the promoter region of the human MMP-1 gene, and this polymorphism has been associated with risk of cancer metastasis and inflammatory diseases.
|
12622858 |
2003 |